Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:11:50 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SLS - SELLAS LIFE SCIENCES GROUP INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SLS - Q1.41.21·1.230.11.21-0.25-17.13,329.43,9674,7301.33  1.34  1.201.914  0.498618:44:1308:4515 min RT 2¢

Recent Trades - Last 10 of 4730
Time ETExPriceChangeVolume
18:44:13Q1.22-0.24396
18:20:21Q1.2105-0.24951
18:20:20Q1.23-0.232,000
18:13:38Q1.2299-0.2301100
17:53:22Q1.2299-0.2301159
17:48:55Q1.2102-0.2498254
17:43:33Q1.21-0.25216
17:39:05Q1.23-0.2315
17:38:04Q1.2299-0.2301100
17:37:03Q1.23-0.231

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-29 08:45U:SLSNews ReleaseSELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
2024-03-28 16:05U:SLSNews ReleaseSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
2024-03-26 07:35U:SLSNews ReleaseSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
2024-03-19 16:05U:SLSNews ReleaseSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
2024-03-19 08:47U:SLSNews ReleaseSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
2024-03-15 09:01U:SLSNews ReleaseSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
2024-03-08 08:00U:SLSNews ReleaseSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
2024-03-01 08:30U:SLSNews ReleaseSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
2024-02-29 08:01U:SLSNews ReleaseSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
2024-02-06 08:30U:SLSNews ReleaseSELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
2024-01-25 08:45U:SLSNews ReleaseSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
2024-01-09 08:30U:SLSNews ReleaseSELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
2024-01-04 09:02U:SLSNews ReleaseSELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
2024-01-03 20:05U:SLSNews ReleaseSELLAS Life Sciences Announces Proposed Public Offering
2024-01-03 07:30U:SLSNews ReleaseSELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
2023-12-27 08:55U:SLSNews ReleaseSELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo ‚ ® in Advanced Malignant Pleural Mesothelioma
2023-12-21 08:15U:SLSNews ReleaseSELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
2023-12-14 08:30U:SLSNews ReleaseSELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
2023-12-13 08:30U:SLSNews ReleaseSELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
2023-12-04 08:47U:SLSNews ReleaseSELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia